Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗,或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

First Posted Date
2024-10-09
Last Posted Date
2024-10-09
Lead Sponsor
Aptevo Therapeutics
Target Recruit Count
39
Registration Number
NCT06634394

Mitoxantrone Hydrochloride Liposome, Standard-dose of Cytarabine and Venetoclax in the Treatment of R/R AML

First Posted Date
2024-10-01
Last Posted Date
2024-10-01
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
20
Registration Number
NCT06621212
Locations
🇨🇳

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

First Posted Date
2024-10-01
Last Posted Date
2024-10-01
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
42
Registration Number
NCT06621199
Locations
🇨🇳

The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Phase Ib Study of Rezatapopt in Combination With Azacitidine or Azacitidine and Venetoclax in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

First Posted Date
2024-09-27
Last Posted Date
2024-11-20
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
25
Registration Number
NCT06616636
Locations
🇺🇸

The University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Chemotherapy-free Regimen of Venetoclax, Azacitidine Plus Orebatinib (VAO Regimen) for Newly Diagnosed ph+ALL

First Posted Date
2024-08-29
Last Posted Date
2024-08-29
Lead Sponsor
The First Affiliated Hospital of Soochow University
Target Recruit Count
30
Registration Number
NCT06578546
Locations
🇨🇳

The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

RIC Allo-HSCT vs. Venetoclax-Based Consolidation in Elderly AML Patients After First CR

First Posted Date
2024-08-26
Last Posted Date
2024-08-26
Lead Sponsor
He Huang
Target Recruit Count
118
Registration Number
NCT06571825
Locations
🇨🇳

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

Phase 2
Not yet recruiting
Conditions
Interventions
First Posted Date
2024-08-16
Last Posted Date
2024-08-20
Lead Sponsor
Institut Paoli-Calmettes
Target Recruit Count
50
Registration Number
NCT06557421
© Copyright 2024. All Rights Reserved by MedPath